RJA
HRTX icon

Raymond James & Associates’s Heron Therapeutics HRTX Stock Holding History

Raymond James & Associates’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$170K Hold
85,463
– – ﹤0.01% 3688
2024
Q2 		$299K Sell
85,463
-2,057
-2% -$6.32K ﹤0.01% 3377
2024
Q1 		$242K Buy
+87,520
New +$220K ﹤0.01% 3505
2021
Q4 		– Sell
-14,081
Closed -$151K – 4206
2021
Q3 		$151K Buy
+14,081
New +$171K ﹤0.01% 3737
2021
Q2 		– Sell
-45,788
Closed -$742K – 4136
2021
Q1 		$742K Buy
45,788
+36,224
+379% +$646K ﹤0.01% 2714
2020
Q4 		$202K Buy
+9,564
New +$166K ﹤0.01% 3397
2020
Q3 		– Sell
-11,684
Closed -$172K – 3630
2020
Q2 		$172K Buy
11,684
+893
+8% +$14.7K ﹤0.01% 3176
2020
Q1 		$127K Sell
10,791
-591
-5% -$11.1K ﹤0.01% 3161
2019
Q4 		$267K Sell
11,382
-3,460
-23% -$76.5K ﹤0.01% 3153
2019
Q3 		$275K Sell
14,842
-16,461
-53% -$303K ﹤0.01% 3075
2019
Q2 		$582K Buy
31,303
+6,448
+26% +$129K ﹤0.01% 2554
2019
Q1 		$607K Buy
24,855
+1,250
+5% +$32.7K ﹤0.01% 2531
2018
Q4 		$612K Sell
23,605
-2,522
-10% -$69.3K ﹤0.01% 2411
2018
Q3 		$827K Sell
26,127
-2,982
-10% -$111K ﹤0.01% 2375
2018
Q2 		$1.13M Buy
29,109
+165
+0.6% +$5.25K ﹤0.01% 2113
2018
Q1 		$799K Buy
+28,944
New +$657K ﹤0.01% 2279

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's HRTX Position: Q3 2024 in Review

Raymond James & Associates held its Heron Therapeutics (HRTX) position steady in Q3 2024 at 85,463 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #3688.

Raymond James & Associates first reported a position in HRTX in Q1 2018 and has held it in 16 quarters since. The position peaked at $1.13M in Q2 2018. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • Raymond James & Associates held 85,463 shares of Heron Therapeutics worth $170K as of Q3 2024.
  • Raymond James & Associates left its Heron Therapeutics share count unchanged in Q3 2024.
  • Heron Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3688 holding.
  • Raymond James & Associates first reported a position in Heron Therapeutics in Q1 2018 and has held it in 16 quarters since.
  • Raymond James & Associates's Heron Therapeutics position peaked at $1.13M in Q2 2018.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.